Role of androgen receptor signaling pathway-related lncRNAs in the prognosis and immune infiltration of breast cancer

Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BR...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 12; no. 1; pp. 20631 - 17
Main Authors Huang, Guo, Cao, Hong, Liu, Guowen, Chen, Juan
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 30.11.2022
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BRCA). Our study screen ARSP-related lncRNAs for the construction of a risk model. The single-sample gene set enrichment analysis (ssGSEA) method was used to detect the differences between the immune responses generated by the patients belonging to the low- and high-risk groups. The relationship between the ARSP-related lncRNAs and TME was explored following the process of cluster analysis. The univariate Cox analysis and the Lasso regression analysis method was used to screen nine of these lncRNAs to develop a risk model. It was observed that risk score could function as an independent prognostic factor, affecting the prognoses of patients suffering from BRCA. The validity of the model was assessed by analyzing the generated calibration curves and a nomogram. Additionally, the effect of the risk score on the extent of immune cell infiltration realized in TME was explored. M2 macrophages correlated positively, whereas NK cells, CD4+ T cells, and naive B cells correlated negatively with the risk score. Results obtained using the cluster analysis indicated that immune scores correlated with clustered subtypes. Finally, the risk score and cluster subtypes were analyzed to study the sensitivity of the patients toward different drugs to identify the appropriate therapeutic agents. The prognoses of patients suffering from BRCA can be accurately predicted by ARSP-related lncRNAs.
AbstractList Abstract Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BRCA). Our study screen ARSP-related lncRNAs for the construction of a risk model. The single-sample gene set enrichment analysis (ssGSEA) method was used to detect the differences between the immune responses generated by the patients belonging to the low- and high-risk groups. The relationship between the ARSP-related lncRNAs and TME was explored following the process of cluster analysis. The univariate Cox analysis and the Lasso regression analysis method was used to screen nine of these lncRNAs to develop a risk model. It was observed that risk score could function as an independent prognostic factor, affecting the prognoses of patients suffering from BRCA. The validity of the model was assessed by analyzing the generated calibration curves and a nomogram. Additionally, the effect of the risk score on the extent of immune cell infiltration realized in TME was explored. M2 macrophages correlated positively, whereas NK cells, CD4+ T cells, and naive B cells correlated negatively with the risk score. Results obtained using the cluster analysis indicated that immune scores correlated with clustered subtypes. Finally, the risk score and cluster subtypes were analyzed to study the sensitivity of the patients toward different drugs to identify the appropriate therapeutic agents. The prognoses of patients suffering from BRCA can be accurately predicted by ARSP-related lncRNAs.
Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BRCA). Our study screen ARSP-related lncRNAs for the construction of a risk model. The single-sample gene set enrichment analysis (ssGSEA) method was used to detect the differences between the immune responses generated by the patients belonging to the low- and high-risk groups. The relationship between the ARSP-related lncRNAs and TME was explored following the process of cluster analysis. The univariate Cox analysis and the Lasso regression analysis method was used to screen nine of these lncRNAs to develop a risk model. It was observed that risk score could function as an independent prognostic factor, affecting the prognoses of patients suffering from BRCA. The validity of the model was assessed by analyzing the generated calibration curves and a nomogram. Additionally, the effect of the risk score on the extent of immune cell infiltration realized in TME was explored. M2 macrophages correlated positively, whereas NK cells, CD4+ T cells, and naive B cells correlated negatively with the risk score. Results obtained using the cluster analysis indicated that immune scores correlated with clustered subtypes. Finally, the risk score and cluster subtypes were analyzed to study the sensitivity of the patients toward different drugs to identify the appropriate therapeutic agents. The prognoses of patients suffering from BRCA can be accurately predicted by ARSP-related lncRNAs.
Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BRCA). Our study screen ARSP-related lncRNAs for the construction of a risk model. The single-sample gene set enrichment analysis (ssGSEA) method was used to detect the differences between the immune responses generated by the patients belonging to the low- and high-risk groups. The relationship between the ARSP-related lncRNAs and TME was explored following the process of cluster analysis. The univariate Cox analysis and the Lasso regression analysis method was used to screen nine of these lncRNAs to develop a risk model. It was observed that risk score could function as an independent prognostic factor, affecting the prognoses of patients suffering from BRCA. The validity of the model was assessed by analyzing the generated calibration curves and a nomogram. Additionally, the effect of the risk score on the extent of immune cell infiltration realized in TME was explored. M2 macrophages correlated positively, whereas NK cells, CD4+ T cells, and naive B cells correlated negatively with the risk score. Results obtained using the cluster analysis indicated that immune scores correlated with clustered subtypes. Finally, the risk score and cluster subtypes were analyzed to study the sensitivity of the patients toward different drugs to identify the appropriate therapeutic agents. The prognoses of patients suffering from BRCA can be accurately predicted by ARSP-related lncRNAs.Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related long non-coding RNAs (ARSP-related lncRNAs) on the process of subtype classification and the tumor microenvironment (TME) of breast cancer (BRCA). Our study screen ARSP-related lncRNAs for the construction of a risk model. The single-sample gene set enrichment analysis (ssGSEA) method was used to detect the differences between the immune responses generated by the patients belonging to the low- and high-risk groups. The relationship between the ARSP-related lncRNAs and TME was explored following the process of cluster analysis. The univariate Cox analysis and the Lasso regression analysis method was used to screen nine of these lncRNAs to develop a risk model. It was observed that risk score could function as an independent prognostic factor, affecting the prognoses of patients suffering from BRCA. The validity of the model was assessed by analyzing the generated calibration curves and a nomogram. Additionally, the effect of the risk score on the extent of immune cell infiltration realized in TME was explored. M2 macrophages correlated positively, whereas NK cells, CD4+ T cells, and naive B cells correlated negatively with the risk score. Results obtained using the cluster analysis indicated that immune scores correlated with clustered subtypes. Finally, the risk score and cluster subtypes were analyzed to study the sensitivity of the patients toward different drugs to identify the appropriate therapeutic agents. The prognoses of patients suffering from BRCA can be accurately predicted by ARSP-related lncRNAs.
ArticleNumber 20631
Author Liu, Guowen
Huang, Guo
Cao, Hong
Chen, Juan
Author_xml – sequence: 1
  givenname: Guo
  surname: Huang
  fullname: Huang, Guo
  organization: Hengyang Medical School, University of South China, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, Cancer Research Institute, University of South China, Department of Breast and Thyroid Surgery, Hengyang Medical School, The Second Affiliated Hospital, University of South China
– sequence: 2
  givenname: Hong
  surname: Cao
  fullname: Cao, Hong
  organization: Department of Breast and Thyroid Surgery, Hengyang Medical School, The Second Affiliated Hospital, University of South China
– sequence: 3
  givenname: Guowen
  surname: Liu
  fullname: Liu, Guowen
  email: liugw8318@163.com
  organization: Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
– sequence: 4
  givenname: Juan
  surname: Chen
  fullname: Chen, Juan
  email: chenjuan@usc.edu.cn
  organization: Department of Radiotherapy, The Second Affiliated Hospital, Hengyang Medical School, University of South China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36450882$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1vFCEYxiemxtbaf8CDIfHiZZTPAS4mTeNHk0aTRs-EgXdm2czCCjOa_veyu622PZQLBJ7nxwPv-7I5iilC07wm-D3BTH0onAitWkxpSwVlpMXPmhOKuWgpo_To3vq4OStljesQVHOiXzTHrOMCK0VPmuU6TYDSgGz0OY0QUQYH2zllVMIY7RTiiLZ2Xv2xN22Gyc7g0RTd9bfzgkJE8wrQthpjKqHsIChsNkuEejaEac52Dinu-H0GW2bkbHSQXzXPBzsVOLudT5ufnz_9uPjaXn3_cnlxftU6wfHcEoIl7wiTPcdCaS5lJ3qtvWOY9mBxNzgK3nlKtPCUD9YK7D3rKOGDUoyx0-bywPXJrs02h43NNybZYPYbKY_G5jm4CYwFrbzSEhym3InBEg9KivqLGijDqrI-Hljbpd_UWyHW100PoA9PYliZMf02WhLaSVkB724BOf1aoMxmE4qDabIR0lIMlZx3neSSVOnbR9J1WnKtxl5FNda62wHf3E_0L8pddatAHQQup1IyDMaFeV-RGjBMhmCz6yVz6CVTe8nse8ngaqWPrHf0J03sYCpVHEfI_2M_4foLvAHbsg
CitedBy_id crossref_primary_10_3389_fcell_2024_1403396
crossref_primary_10_3390_cancers16162920
crossref_primary_10_3389_fimmu_2023_1194300
crossref_primary_10_18632_aging_205946
crossref_primary_10_1016_j_heliyon_2024_e33930
crossref_primary_10_1016_j_ncrna_2024_01_014
crossref_primary_10_1080_10286020_2024_2390508
crossref_primary_10_3390_cancers16234043
crossref_primary_10_3892_ijo_2023_5595
crossref_primary_10_1002_tox_24205
Cites_doi 10.1093/nar/gkaa970
10.1186/s12935-020-01472-9
10.3892/or.2021.8139
10.1038/nmeth.3337
10.3389/fgene.2021.748279
10.1016/j.bbcan.2018.05.004
10.1016/j.celrep.2019.12.011
10.1080/21655979.2021.1969833
10.1001/jamanetworkopen.2021.14904
10.1086/302366
10.1002/jcp.29847
10.1056/NEJMoa1701830
10.1097/med.0000000000000251
10.26355/eurrev_202004_20824
10.7150/jca.29670
10.1038/s41598-022-14897-1
10.1038/s41418-018-0123-6
10.1155/2021/6290261
10.1016/j.ajhg.2020.09.001
10.1016/j.biopha.2019.108718
10.3322/caac.21609
10.1155/2020/6827057
10.1159/000456910
10.2147/cmar.S322195
10.1007/s10549-009-0436-8
10.1186/bcr3599
10.1073/pnas.0506580102
10.3390/molecules25020358
10.1111/jcmm.14721
10.3389/fcell.2021.729965
10.1016/j.mce.2021.111324
10.1016/s1470-2045(14)70080-4
10.1093/jnci/djz208
10.1159/000499931
10.3389/fonc.2020.582863
10.1038/s41419-020-02856-5
10.1593/neo.08274
10.1016/j.ymeth.2017.06.010
10.1038/modpathol.2011.54
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-022-25231-0
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE


CrossRef
MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 17
ExternalDocumentID oai_doaj_org_article_ae98d897ec024c5fa1de8752049e2308
PMC9712677
36450882
10_1038_s41598_022_25231_0
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: The Guiding Project of Clinical Medical Technology Innovation in Hunan Province
  grantid: 2021SK51706
– fundername: The Scientific Research Program of Hunan Provincial Health Commission
  grantid: 20201969
– fundername: The Clinical Research Center for Breast & Thyroid Disease Prevention in Hunan Province
  grantid: 2018SK4001
– fundername: The Second People's Hospital of Shenzhen High-level Capital Project
  grantid: 4004009
– fundername: ;
  grantid: 2021SK51706
– fundername: ;
  grantid: 4004009
– fundername: ;
  grantid: 2018SK4001
– fundername: ;
  grantid: 20201969
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AARCD
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c540t-110746137b4058947765b99dc302bea06fc2edcd2195d24faa50dd36214f88333
IEDL.DBID M48
ISSN 2045-2322
IngestDate Wed Aug 27 01:13:54 EDT 2025
Thu Aug 21 18:38:47 EDT 2025
Mon Jul 21 10:46:17 EDT 2025
Wed Aug 13 07:38:39 EDT 2025
Thu Jan 02 22:52:58 EST 2025
Tue Jul 01 00:55:33 EDT 2025
Thu Apr 24 23:02:00 EDT 2025
Fri Feb 21 02:38:51 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2022. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-110746137b4058947765b99dc302bea06fc2edcd2195d24faa50dd36214f88333
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-022-25231-0
PMID 36450882
PQID 2742909967
PQPubID 2041939
PageCount 17
ParticipantIDs doaj_primary_oai_doaj_org_article_ae98d897ec024c5fa1de8752049e2308
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9712677
proquest_miscellaneous_2744667471
proquest_journals_2742909967
pubmed_primary_36450882
crossref_citationtrail_10_1038_s41598_022_25231_0
crossref_primary_10_1038_s41598_022_25231_0
springer_journals_10_1038_s41598_022_25231_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-11-30
PublicationDateYYYYMMDD 2022-11-30
PublicationDate_xml – month: 11
  year: 2022
  text: 2022-11-30
  day: 30
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References ZhongHZengGHeLOverexpression of the lncRNA AC012213.3 promotes proliferation, migration and invasion of breast cancer via RAD54B/PI3K/AKT axis and is associated with worse patient prognosisCancer Manag. Res.2021137213722310.2147/cmar.S322195345570388453444
HuangZLiJChenJChenDConstruction of prognostic risk model of 5-methylcytosine-related long non-coding RNAs and evaluation of the characteristics of tumor-infiltrating immune cells in breast cancerFront. Genet.2021121:CAS:528:DC%2BB38XjvFCrtL4%3D10.3389/fgene.2021.748279347774738585929
LiTLINC00702/miR-4652–3p/ZEB1 axis promotes the progression of malignant meningioma through activating Wnt/β-catenin pathwayBiomed. Pharmacother. Biomed. Pharmacother.20191131087181:CAS:528:DC%2BC1MXktlKhsr0%3D10.1016/j.biopha.2019.10871830849635
YuDWangXJinZLinc00702 inhibits cell growth and metastasis through regulating PTEN in colorectal cancerEur. Rev. Med. Pharmacol. Sci.202024362436321:STN:280:DC%2BB38zptFCitg%3D%3D10.26355/eurrev_202004_2082432329837
RebbeckTModification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeatAm. J. Hum. Genet.199964137113771:CAS:528:DyaK1MXlt1ajt78%3D10.1086/302366102052681377873
CollinsLAndrogen receptor expression in breast cancer in relation to molecular phenotype: Results from the Nurses' Health StudyMod. Pathol.20112492493110.1038/modpathol.2011.54215522123128675
JahanNJonesCRahmanRAndrogen receptor expression in breast cancer: Implications on prognosis and treatment, a brief reviewMol. Cell. Endocrinol.20215311:CAS:528:DC%2BB3MXhtFCmsr7F10.1016/j.mce.2021.11132434000352
CochraneDRole of the androgen receptor in breast cancer and preclinical analysis of enzalutamideBreast Cancer Res. BCR201416R71:CAS:528:DC%2BC2MXivFGjsb0%3D10.1186/bcr359924451109
KanehisaMFurumichiMSatoYIshiguro-WatanabeMTanabeMKEGG: Integrating viruses and cellular organismsNucleic Acids Res.202149D545D5511:CAS:528:DC%2BB3MXntlejsLw%3D10.1093/nar/gkaa97033125081
BalicMThomssenCWürstleinRGnantMHarbeckNSGallenVSt. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatmentBreast Care (Basel, Switzerland)20191410311010.1159/00049993131798382
YaoMLINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progressionCell Death Dis.2020116381:CAS:528:DC%2BB3cXhs1ygtrjI10.1038/s41419-020-02856-5328013007429955
WangXZhangJLiuXWeiBZhanLLong noncoding RNAs in endometriosis: Biological functions, expressions, and mechanismsJ. Cell. Physiol.20212366141:CAS:528:DC%2BB3cXhtFSgsbbK10.1002/jcp.2984732506425
YaoYIntegrated analysis of co-expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancerJ. Cell Mol. Med.201923841084191:CAS:528:DC%2BC1MXitFOrs7zM10.1111/jcmm.14721316130586850943
GianniLNeoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohortLancet Oncol.2014156406471:CAS:528:DC%2BC2cXkslWiu78%3D10.1016/s1470-2045(14)70080-424657003
ShuaiCYangXPanHHanWEstrogen receptor downregulates expression of PD-1/PD-L1 and infiltration of CD8 T cells by inhibiting IL-17 signaling transduction in breast cancerFront. Oncol.20201010.3389/fonc.2020.582863331022397545792
NascimentoGMolecular characterization of Koolen De Vries syndrome in two girls with idiopathic intellectual disability from central BrazilMol. Syndromol.201781551601:CAS:528:DC%2BC2sXotVOjur4%3D10.1159/000456910285884375448449
DaiHHIF1α regulates IL17 signaling pathway influencing sensitivity of taxane-based chemotherapy for breast cancerFront. Cell Dev. Biol.2021910.3389/fcell.2021.729965345951778476907
Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.70, 313. https://doi.org/10.3322/caac.21609 (2020).
HuangGZhouJChenJLiuGIdentification of pyroptosis related subtypes and tumor microenvironment infiltration characteristics in breast cancerSci. Rep.202212106402022NatSR..1210640H1:CAS:528:DC%2BB38Xhslajs7jP10.1038/s41598-022-14897-1357391829226023
NewmanARobust enumeration of cell subsets from tissue expression profilesNat. Methods2015124534571:CAS:528:DC%2BC2MXlsVOgu7Y%3D10.1038/nmeth.3337258228004739640
YamaguchiMAndrogens enhance the ability of intratumoral macrophages to promote breast cancer progressionOncol. Rep.202110.3892/or.2021.813934278480
NaderiAHughes-DaviesLA functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancerNeoplasia (New York, NY)2008105425481:CAS:528:DC%2BD1cXoslWgtb4%3D10.1593/neo.08274
YuZLong non-coding RNA COL4A2-AS1 facilitates cell proliferation and glycolysis of colorectal cancer cells via miR-20b-5p/hypoxia inducible factor 1 alpha subunit axisBioengineered202112625162631:CAS:528:DC%2BB3MXhvFKksr7F10.1080/21655979.2021.1969833344774768806750
ChenWIdentification of a tumor microenvironment-related gene signature indicative of disease prognosis and treatment response in colon cancerOxid. Med. Cell. Longev.2021202162902611:CAS:528:DC%2BB38XjvFKnu70%3D10.1155/2021/6290261344976818420973
BarecheYUnraveling triple-negative breast cancer tumor microenvironment heterogeneity: Towards an optimized treatment approachJ. Natl Cancer Inst.20201127087191:CAS:528:DC%2BB3cXis1CjsLfF10.1093/jnci/djz20831665482
AnestisAZoiIPapavassiliouAKaramouzisMAndrogen receptor in breast cancer-clinical and preclinical research insightsMolecules (Basel, Switzerland).202010.3390/molecules25020358319522727024330
DarHAssessment of 25-year survival of women with estrogen receptor-positive/ERBB2-negative breast cancer treated with and without tamoxifen therapy: A secondary analysis of data from the stockholm tamoxifen randomized clinical trialJAMA Netw. Open2021410.1001/jamanetworkopen.2021.14904341909958246315
BiFChenYYangQSignificance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancerCancer Cell Int.2020203731:CAS:528:DC%2BB3cXhsFGmtr%2FF10.1186/s12935-020-01472-9327741677405355
SubramanianAGene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProc. Natl. Acad. Sci. U.S.A.200510215545155501:CAS:528:DC%2BD2MXht1ShtrnO10.1073/pnas.0506580102161995171239896
CollinaFHOTAIRLncRNA up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast CancerJ. Cancer201910201820241:CAS:528:DC%2BB3cXjslGitbs%3D10.7150/jca.29670312055626548158
PanH20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 yearsN. Engl. J. Med.20173771836184610.1056/NEJMoa1701830291174985734609
ShiYYangFHuangDGuanXAndrogen blockade based clinical trials landscape in triple negative breast cancerBiochim. Biophys. Acta. Rev. Cancer201818702832901:CAS:528:DC%2BC1cXhtFGjsbvL10.1016/j.bbcan.2018.05.00429807045
SchmidtKTargeting the oncogenic long non-coding RNA SLNCR1 by blocking its sequence-specific binding to the androgen receptorCell Rep.202030541554.e5451:CAS:528:DC%2BB3cXotFelur4%3D10.1016/j.celrep.2019.12.011319404957067293
KramerIBreast cancer polygenic risk score and contralateral breast cancer riskAm. J. Hum. Genet.20201078378481:CAS:528:DC%2BB3cXitVWrurzJ10.1016/j.ajhg.2020.09.001330222217675034
LiuCWangXGenchevGLuHMulti-omics facilitated variable selection in Cox-regression model for cancer prognosis predictionMethods (San Diego, Calif.)20171241001071:CAS:528:DC%2BC2sXhtF2qu7nL10.1016/j.ymeth.2017.06.01028627406
ZhouWPangYYaoYQiaoHDevelopment of a Ten-lncRNA signature prognostic model for breast cancer survival: A study with the TCGA databaseAnal. Cell. Pathol. (Amst.)2020202068270571:CAS:528:DC%2BB3cXitlWru73N10.1155/2020/682705732908814
De AmicisFAndrogen receptor overexpression induces tamoxifen resistance in human breast cancer cellsBreast Cancer Res. Treat.20101211111:CAS:528:DC%2BC3cXkvVymtL0%3D10.1007/s10549-009-0436-819533338
McNamaraKSasanoHAndrogen and breast cancer: An updateCurr. Opin. Endocrinol. Diabetes Obes.2016232492561:CAS:528:DC%2BC28XmvFCisLc%3D10.1097/med.000000000000025126945136
YangFAn androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancerCell Death Differ.201825220922201:CAS:528:DC%2BC1cXhtVGgu7%2FL10.1038/s41418-018-0123-6298445706261952
LeTThe ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancerAm. J. Cancer Res.2022121761971:CAS:528:DC%2BB38Xht1KlurbO351410128822277
W Chen (25231_CR23) 2021; 2021
Z Yu (25231_CR29) 2021; 12
A Newman (25231_CR21) 2015; 12
L Gianni (25231_CR2) 2014; 15
H Pan (25231_CR3) 2017; 377
Y Shi (25231_CR12) 2018; 1870
A Subramanian (25231_CR20) 2005; 102
K Schmidt (25231_CR15) 2020; 30
C Liu (25231_CR17) 2017; 124
G Nascimento (25231_CR27) 2017; 8
25231_CR1
D Cochrane (25231_CR10) 2014; 16
F Collina (25231_CR34) 2019; 10
A Naderi (25231_CR11) 2008; 10
M Yamaguchi (25231_CR40) 2021
T Li (25231_CR33) 2019; 113
T Rebbeck (25231_CR13) 1999; 64
C Shuai (25231_CR37) 2020; 10
L Collins (25231_CR6) 2011; 24
X Wang (25231_CR14) 2021; 236
D Yu (25231_CR32) 2020; 24
F Yang (25231_CR35) 2018; 25
Z Huang (25231_CR31) 2021; 12
I Kramer (25231_CR24) 2020; 107
A Anestis (25231_CR25) 2020
H Zhong (25231_CR26) 2021; 13
H Dar (25231_CR4) 2021; 4
K McNamara (25231_CR7) 2016; 23
M Balic (25231_CR5) 2019; 14
F De Amicis (25231_CR9) 2010; 121
N Jahan (25231_CR8) 2021; 531
G Huang (25231_CR18) 2022; 12
F Bi (25231_CR22) 2020; 20
Y Yao (25231_CR30) 2019; 23
M Kanehisa (25231_CR19) 2021; 49
Y Bareche (25231_CR39) 2020; 112
T Le (25231_CR38) 2022; 12
H Dai (25231_CR36) 2021; 9
W Zhou (25231_CR28) 2020; 2020
M Yao (25231_CR16) 2020; 11
References_xml – reference: NaderiAHughes-DaviesLA functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancerNeoplasia (New York, NY)2008105425481:CAS:528:DC%2BD1cXoslWgtb4%3D10.1593/neo.08274
– reference: LiuCWangXGenchevGLuHMulti-omics facilitated variable selection in Cox-regression model for cancer prognosis predictionMethods (San Diego, Calif.)20171241001071:CAS:528:DC%2BC2sXhtF2qu7nL10.1016/j.ymeth.2017.06.01028627406
– reference: LeTThe ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancerAm. J. Cancer Res.2022121761971:CAS:528:DC%2BB38Xht1KlurbO351410128822277
– reference: AnestisAZoiIPapavassiliouAKaramouzisMAndrogen receptor in breast cancer-clinical and preclinical research insightsMolecules (Basel, Switzerland).202010.3390/molecules25020358319522727024330
– reference: GianniLNeoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohortLancet Oncol.2014156406471:CAS:528:DC%2BC2cXkslWiu78%3D10.1016/s1470-2045(14)70080-424657003
– reference: McNamaraKSasanoHAndrogen and breast cancer: An updateCurr. Opin. Endocrinol. Diabetes Obes.2016232492561:CAS:528:DC%2BC28XmvFCisLc%3D10.1097/med.000000000000025126945136
– reference: ZhouWPangYYaoYQiaoHDevelopment of a Ten-lncRNA signature prognostic model for breast cancer survival: A study with the TCGA databaseAnal. Cell. Pathol. (Amst.)2020202068270571:CAS:528:DC%2BB3cXitlWru73N10.1155/2020/682705732908814
– reference: DaiHHIF1α regulates IL17 signaling pathway influencing sensitivity of taxane-based chemotherapy for breast cancerFront. Cell Dev. Biol.2021910.3389/fcell.2021.729965345951778476907
– reference: CochraneDRole of the androgen receptor in breast cancer and preclinical analysis of enzalutamideBreast Cancer Res. BCR201416R71:CAS:528:DC%2BC2MXivFGjsb0%3D10.1186/bcr359924451109
– reference: BiFChenYYangQSignificance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancerCancer Cell Int.2020203731:CAS:528:DC%2BB3cXhsFGmtr%2FF10.1186/s12935-020-01472-9327741677405355
– reference: RebbeckTModification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeatAm. J. Hum. Genet.199964137113771:CAS:528:DyaK1MXlt1ajt78%3D10.1086/302366102052681377873
– reference: NascimentoGMolecular characterization of Koolen De Vries syndrome in two girls with idiopathic intellectual disability from central BrazilMol. Syndromol.201781551601:CAS:528:DC%2BC2sXotVOjur4%3D10.1159/000456910285884375448449
– reference: ChenWIdentification of a tumor microenvironment-related gene signature indicative of disease prognosis and treatment response in colon cancerOxid. Med. Cell. Longev.2021202162902611:CAS:528:DC%2BB38XjvFKnu70%3D10.1155/2021/6290261344976818420973
– reference: LiTLINC00702/miR-4652–3p/ZEB1 axis promotes the progression of malignant meningioma through activating Wnt/β-catenin pathwayBiomed. Pharmacother. Biomed. Pharmacother.20191131087181:CAS:528:DC%2BC1MXktlKhsr0%3D10.1016/j.biopha.2019.10871830849635
– reference: CollinaFHOTAIRLncRNA up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast CancerJ. Cancer201910201820241:CAS:528:DC%2BB3cXjslGitbs%3D10.7150/jca.29670312055626548158
– reference: PanH20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 yearsN. Engl. J. Med.20173771836184610.1056/NEJMoa1701830291174985734609
– reference: BarecheYUnraveling triple-negative breast cancer tumor microenvironment heterogeneity: Towards an optimized treatment approachJ. Natl Cancer Inst.20201127087191:CAS:528:DC%2BB3cXis1CjsLfF10.1093/jnci/djz20831665482
– reference: WangXZhangJLiuXWeiBZhanLLong noncoding RNAs in endometriosis: Biological functions, expressions, and mechanismsJ. Cell. Physiol.20212366141:CAS:528:DC%2BB3cXhtFSgsbbK10.1002/jcp.2984732506425
– reference: CollinsLAndrogen receptor expression in breast cancer in relation to molecular phenotype: Results from the Nurses' Health StudyMod. Pathol.20112492493110.1038/modpathol.2011.54215522123128675
– reference: YamaguchiMAndrogens enhance the ability of intratumoral macrophages to promote breast cancer progressionOncol. Rep.202110.3892/or.2021.813934278480
– reference: ZhongHZengGHeLOverexpression of the lncRNA AC012213.3 promotes proliferation, migration and invasion of breast cancer via RAD54B/PI3K/AKT axis and is associated with worse patient prognosisCancer Manag. Res.2021137213722310.2147/cmar.S322195345570388453444
– reference: YuZLong non-coding RNA COL4A2-AS1 facilitates cell proliferation and glycolysis of colorectal cancer cells via miR-20b-5p/hypoxia inducible factor 1 alpha subunit axisBioengineered202112625162631:CAS:528:DC%2BB3MXhvFKksr7F10.1080/21655979.2021.1969833344774768806750
– reference: YaoMLINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progressionCell Death Dis.2020116381:CAS:528:DC%2BB3cXhs1ygtrjI10.1038/s41419-020-02856-5328013007429955
– reference: De AmicisFAndrogen receptor overexpression induces tamoxifen resistance in human breast cancer cellsBreast Cancer Res. Treat.20101211111:CAS:528:DC%2BC3cXkvVymtL0%3D10.1007/s10549-009-0436-819533338
– reference: ShiYYangFHuangDGuanXAndrogen blockade based clinical trials landscape in triple negative breast cancerBiochim. Biophys. Acta. Rev. Cancer201818702832901:CAS:528:DC%2BC1cXhtFGjsbvL10.1016/j.bbcan.2018.05.00429807045
– reference: DarHAssessment of 25-year survival of women with estrogen receptor-positive/ERBB2-negative breast cancer treated with and without tamoxifen therapy: A secondary analysis of data from the stockholm tamoxifen randomized clinical trialJAMA Netw. Open2021410.1001/jamanetworkopen.2021.14904341909958246315
– reference: JahanNJonesCRahmanRAndrogen receptor expression in breast cancer: Implications on prognosis and treatment, a brief reviewMol. Cell. Endocrinol.20215311:CAS:528:DC%2BB3MXhtFCmsr7F10.1016/j.mce.2021.11132434000352
– reference: YuDWangXJinZLinc00702 inhibits cell growth and metastasis through regulating PTEN in colorectal cancerEur. Rev. Med. Pharmacol. Sci.202024362436321:STN:280:DC%2BB38zptFCitg%3D%3D10.26355/eurrev_202004_2082432329837
– reference: HuangGZhouJChenJLiuGIdentification of pyroptosis related subtypes and tumor microenvironment infiltration characteristics in breast cancerSci. Rep.202212106402022NatSR..1210640H1:CAS:528:DC%2BB38Xhslajs7jP10.1038/s41598-022-14897-1357391829226023
– reference: Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.70, 313. https://doi.org/10.3322/caac.21609 (2020).
– reference: HuangZLiJChenJChenDConstruction of prognostic risk model of 5-methylcytosine-related long non-coding RNAs and evaluation of the characteristics of tumor-infiltrating immune cells in breast cancerFront. Genet.2021121:CAS:528:DC%2BB38XjvFCrtL4%3D10.3389/fgene.2021.748279347774738585929
– reference: KanehisaMFurumichiMSatoYIshiguro-WatanabeMTanabeMKEGG: Integrating viruses and cellular organismsNucleic Acids Res.202149D545D5511:CAS:528:DC%2BB3MXntlejsLw%3D10.1093/nar/gkaa97033125081
– reference: YaoYIntegrated analysis of co-expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancerJ. Cell Mol. Med.201923841084191:CAS:528:DC%2BC1MXitFOrs7zM10.1111/jcmm.14721316130586850943
– reference: BalicMThomssenCWürstleinRGnantMHarbeckNSGallenVSt. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatmentBreast Care (Basel, Switzerland)20191410311010.1159/00049993131798382
– reference: KramerIBreast cancer polygenic risk score and contralateral breast cancer riskAm. J. Hum. Genet.20201078378481:CAS:528:DC%2BB3cXitVWrurzJ10.1016/j.ajhg.2020.09.001330222217675034
– reference: ShuaiCYangXPanHHanWEstrogen receptor downregulates expression of PD-1/PD-L1 and infiltration of CD8 T cells by inhibiting IL-17 signaling transduction in breast cancerFront. Oncol.20201010.3389/fonc.2020.582863331022397545792
– reference: SchmidtKTargeting the oncogenic long non-coding RNA SLNCR1 by blocking its sequence-specific binding to the androgen receptorCell Rep.202030541554.e5451:CAS:528:DC%2BB3cXotFelur4%3D10.1016/j.celrep.2019.12.011319404957067293
– reference: SubramanianAGene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProc. Natl. Acad. Sci. U.S.A.200510215545155501:CAS:528:DC%2BD2MXht1ShtrnO10.1073/pnas.0506580102161995171239896
– reference: NewmanARobust enumeration of cell subsets from tissue expression profilesNat. Methods2015124534571:CAS:528:DC%2BC2MXlsVOgu7Y%3D10.1038/nmeth.3337258228004739640
– reference: YangFAn androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancerCell Death Differ.201825220922201:CAS:528:DC%2BC1cXhtVGgu7%2FL10.1038/s41418-018-0123-6298445706261952
– volume: 49
  start-page: D545
  year: 2021
  ident: 25231_CR19
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkaa970
– volume: 20
  start-page: 373
  year: 2020
  ident: 25231_CR22
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-020-01472-9
– year: 2021
  ident: 25231_CR40
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2021.8139
– volume: 12
  start-page: 453
  year: 2015
  ident: 25231_CR21
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.3337
– volume: 12
  year: 2021
  ident: 25231_CR31
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2021.748279
– volume: 1870
  start-page: 283
  year: 2018
  ident: 25231_CR12
  publication-title: Biochim. Biophys. Acta. Rev. Cancer
  doi: 10.1016/j.bbcan.2018.05.004
– volume: 30
  start-page: 541
  year: 2020
  ident: 25231_CR15
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2019.12.011
– volume: 12
  start-page: 6251
  year: 2021
  ident: 25231_CR29
  publication-title: Bioengineered
  doi: 10.1080/21655979.2021.1969833
– volume: 4
  year: 2021
  ident: 25231_CR4
  publication-title: JAMA Netw. Open
  doi: 10.1001/jamanetworkopen.2021.14904
– volume: 64
  start-page: 1371
  year: 1999
  ident: 25231_CR13
  publication-title: Am. J. Hum. Genet.
  doi: 10.1086/302366
– volume: 236
  start-page: 6
  year: 2021
  ident: 25231_CR14
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.29847
– volume: 12
  start-page: 176
  year: 2022
  ident: 25231_CR38
  publication-title: Am. J. Cancer Res.
– volume: 377
  start-page: 1836
  year: 2017
  ident: 25231_CR3
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1701830
– volume: 23
  start-page: 249
  year: 2016
  ident: 25231_CR7
  publication-title: Curr. Opin. Endocrinol. Diabetes Obes.
  doi: 10.1097/med.0000000000000251
– volume: 24
  start-page: 3624
  year: 2020
  ident: 25231_CR32
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
  doi: 10.26355/eurrev_202004_20824
– volume: 10
  start-page: 2018
  year: 2019
  ident: 25231_CR34
  publication-title: J. Cancer
  doi: 10.7150/jca.29670
– volume: 12
  start-page: 10640
  year: 2022
  ident: 25231_CR18
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-022-14897-1
– volume: 25
  start-page: 2209
  year: 2018
  ident: 25231_CR35
  publication-title: Cell Death Differ.
  doi: 10.1038/s41418-018-0123-6
– volume: 2021
  start-page: 6290261
  year: 2021
  ident: 25231_CR23
  publication-title: Oxid. Med. Cell. Longev.
  doi: 10.1155/2021/6290261
– volume: 107
  start-page: 837
  year: 2020
  ident: 25231_CR24
  publication-title: Am. J. Hum. Genet.
  doi: 10.1016/j.ajhg.2020.09.001
– volume: 113
  start-page: 108718
  year: 2019
  ident: 25231_CR33
  publication-title: Biomed. Pharmacother. Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2019.108718
– ident: 25231_CR1
  doi: 10.3322/caac.21609
– volume: 2020
  start-page: 6827057
  year: 2020
  ident: 25231_CR28
  publication-title: Anal. Cell. Pathol. (Amst.)
  doi: 10.1155/2020/6827057
– volume: 8
  start-page: 155
  year: 2017
  ident: 25231_CR27
  publication-title: Mol. Syndromol.
  doi: 10.1159/000456910
– volume: 13
  start-page: 7213
  year: 2021
  ident: 25231_CR26
  publication-title: Cancer Manag. Res.
  doi: 10.2147/cmar.S322195
– volume: 121
  start-page: 1
  year: 2010
  ident: 25231_CR9
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-009-0436-8
– volume: 16
  start-page: R7
  year: 2014
  ident: 25231_CR10
  publication-title: Breast Cancer Res. BCR
  doi: 10.1186/bcr3599
– volume: 102
  start-page: 15545
  year: 2005
  ident: 25231_CR20
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
  doi: 10.1073/pnas.0506580102
– year: 2020
  ident: 25231_CR25
  publication-title: Molecules (Basel, Switzerland).
  doi: 10.3390/molecules25020358
– volume: 23
  start-page: 8410
  year: 2019
  ident: 25231_CR30
  publication-title: J. Cell Mol. Med.
  doi: 10.1111/jcmm.14721
– volume: 9
  year: 2021
  ident: 25231_CR36
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2021.729965
– volume: 531
  year: 2021
  ident: 25231_CR8
  publication-title: Mol. Cell. Endocrinol.
  doi: 10.1016/j.mce.2021.111324
– volume: 15
  start-page: 640
  year: 2014
  ident: 25231_CR2
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(14)70080-4
– volume: 112
  start-page: 708
  year: 2020
  ident: 25231_CR39
  publication-title: J. Natl Cancer Inst.
  doi: 10.1093/jnci/djz208
– volume: 14
  start-page: 103
  year: 2019
  ident: 25231_CR5
  publication-title: Breast Care (Basel, Switzerland)
  doi: 10.1159/000499931
– volume: 10
  year: 2020
  ident: 25231_CR37
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.582863
– volume: 11
  start-page: 638
  year: 2020
  ident: 25231_CR16
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-020-02856-5
– volume: 10
  start-page: 542
  year: 2008
  ident: 25231_CR11
  publication-title: Neoplasia (New York, NY)
  doi: 10.1593/neo.08274
– volume: 124
  start-page: 100
  year: 2017
  ident: 25231_CR17
  publication-title: Methods (San Diego, Calif.)
  doi: 10.1016/j.ymeth.2017.06.010
– volume: 24
  start-page: 924
  year: 2011
  ident: 25231_CR6
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2011.54
SSID ssj0000529419
Score 2.4285417
Snippet Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling pathway-related...
Abstract Androgen receptor (AR) is strong association with breast cancer (BRCA). We aimed to investigate the effect of the androgen receptor signaling...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 20631
SubjectTerms 692/4028
692/499
Androgen receptors
Androgens
Breast cancer
Breast Neoplasms - genetics
CD4 antigen
Cluster analysis
Female
Gene set enrichment analysis
Humanities and Social Sciences
Humans
Immunosuppressive agents
Infiltration
Lymphocytes B
Lymphocytes T
Macrophages
Metastases
multidisciplinary
Nomograms
Non-coding RNA
Prognosis
Receptors, Androgen - genetics
Regression analysis
Risk groups
RNA, Long Noncoding - genetics
Science
Science (multidisciplinary)
Signal Transduction
Tumor microenvironment
Tumor Microenvironment - genetics
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOiltE0fTpOiQm-tiS3LknVMQkIINIfQQG5ClkbUsNgh3qXk33dG9m6zfV56XWm9Ws2M5xtm5hvGPjhwEHV0uYFK5lLXMm9EQMNro241CFFKak7-fKnOr-XFTX3zYNQX1YRN9MDTxR06ME1ojAaP3sTX0ZUBEGMLRLaA8Dm1-aLPexBMTazewsjSzF0yRdUcjuipqJsMYy-BwRfG0FueKBH2_w5l_los-VPGNDmis2fs6Ywg-dF08ufsEfQv2ONppuT9LltdDQvgQ-SOqAhQPTi-0-AWQ2tOtRqO2s85zSH-5u7z1MkCgS96f3V5NPKu5wgIORVt9cPYjfQQ3lELCeBa7BYzyS49v6Vy9iX3pDZ3L9n12emXk_N8nq2Qe8Roy5zCPomuXLeSBgtKrVXdGhN8VYgWXKGiF_ifA77Q6iBkdK4uQkBvV8pI84mrV2ynH3p4w3jQRTQiFsFhdOMkQoaofaNiJUHWUcmMlet7tn4mHqf5FwubEuBVYyfZWJSNTbKxRcY-br5zO9Fu_HX3MYlvs5Mos9MHqEh2ViT7L0XK2P5a-Ha249FSItsgiFY6Y-83y2iBlFZxPQyrtEcqRcF9xl5PurI5CSV5KYjJmN7Soq2jbq_03dfE8m10KZTG3_201rcfx_rzVez9j6t4y54IMpTEcLnPdpZ3KzhA7LVs3yUz-w6EVSmV
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4k1KQUbiBlETx7HjEyqIqkKih4pKe7McPyDSKlk2u0L9951xvKmWR6-xkziZGc98nhch74w3PshgcuUrnnNZ87xhDgSvDbKVnrGSY3Lyt3Nxdsm_LupFOnAbU1jlbk-MG7UbLJ6RH6NLUYE5I-TH1a8cu0ahdzW10LhL7mHpMuRquZDzGQt6sXipUq5MUTXHI-grzCkDBMYAggGS3tNHsWz_v2zNv0Mm__CbRnV0-og8THYkPZkI_5jc8f0Tcn_qLHn1lGwvhqWnQ6AGCxIAk1DY2fwKADbFiA2DSegUuxH_Nld5zGfxji57e3F-MtKup2AWUgzd6oexG_EhtMNEEg9joVumUrv4_BaD2jfUIvOsn5HL0y_fP5_lqcNCbsFS2-QI_jgodNlybC_IpRR1q5SzVcFabwoRLINvdrCt1Y7xYExdOAc6r-QBuxRXz8lBP_T-JaFOFkGxUDgDGMdwMByCtI0IFfe8DoJnpNz9Z21T-XHsgrHU0Q1eNXqijQba6EgbXWTk_XzPaiq-cevsT0i-eSYWzo4XhvUPneRQG68a1yjpLRgntg6mdB4gGwOg5AGNNRk52hFfJ2ke9Q3vZeTtPAxyiM4V0_thG-dwIRDiZ-TFxCvzStDVi1AmI3KPi_aWuj_Sdz9jrW8lSyYkvPfDjt9ulvX_X3F4-1e8Ig8YikCsYHlEDjbrrX8NttWmfRMF6BrnoiFh
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6VVkhcUMuroS0yEjeISBwnjo8LoqpWoodCpd4sJ7Yh0iqpNrtC_ffMOA-0UJC4rp2sk5mx58vMfAPwxjjjvPQmVi4TsZC5iEtu0fAqLyvpOE8FFSd_viwursXyJr_ZAz7VwoSk_UBpGbbpKTvsfY8HDRWDIXTiiJ0QAj-AA6JqR90-WCyWX5bzlxWKXYlUjRUySVbec_HOKRTI-u_zMP9MlPwtWhoOofNDeDx6j2wxrPcI9lz7BB4O_STvnsL2qls51nlmiIYAVYPhfuZuEVYzytMwVHrOqAfxD3MXhyoWZ9mqra8uFz1rWobOIKOErbbrm55uwhoqH3E45pvVSLBL968olX3DalKZ9TO4Pv_09eNFPPZViGv0zzYxQT6Bx7isBDUVFFIWeaWUrbOEV84kha85PrPFzSy3XHhj8sRaPOlS4ak3cfYc9tuudcfArEy84j6xBpGNEegueFmXhc-EE7kvRATp9J51PZKOU--LlQ7B76zUg2w0ykYH2egkgrfzNbcD5cY_Z38g8c0ziS47_NCtv-lRfbRxqrSlkq5Gl6TOvUmtQ6DGER45xGBlBKeT8PVow72mILZCB7qQEbyeh9H6KKRiWtdtwxxRFATsI3gx6Mq8EgrwEoCJQO5o0c5Sd0fa5ntg-FYy5YXE_3036duvZf39Vbz8v-kn8IiTSQQey1PY36y37gw9rE31ajSpn39_IFo
  priority: 102
  providerName: Springer Nature
Title Role of androgen receptor signaling pathway-related lncRNAs in the prognosis and immune infiltration of breast cancer
URI https://link.springer.com/article/10.1038/s41598-022-25231-0
https://www.ncbi.nlm.nih.gov/pubmed/36450882
https://www.proquest.com/docview/2742909967
https://www.proquest.com/docview/2744667471
https://pubmed.ncbi.nlm.nih.gov/PMC9712677
https://doaj.org/article/ae98d897ec024c5fa1de8752049e2308
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9NAEB_uA8EX8dvoWVbwTaPJZpNNHkR65Y6jcEWqhb6FTXb3DITk7Afa_96ZTVqpVp98KmQ36XZnJjO_zs5vAF4ro4yVVvmZiYQvZCz8lGs0vMLKQhrOQ0HFydeT5GomxvN4fgTbdkf9Bi4PQjvqJzVb1O9-fNt8RIP_0JWMp--X6ISoUAxhFUdchfD4GE7RM0nqaHDdh_sd1zfPRJj1tTOHb93zT47G_1Ds-ecRyt_yqM49Xd6He31cyYadIjyAI9M8hDtdp8nNI1hP29qw1jJFBAWoNAzfdOYWATejExyKitIZdSf-rja-q28xmtVNOZ0Ml6xqGIaJjI5yNe2yWtJDWEWFJQbHbFX31Lv0_IIOua9YScq0eAyzy4svoyu_77jglxi5rXwCgwIdvCwEtRsUUiZxkWW6jAJeGBUktuT4mzW-5mLNhVUqDrRGHxgKS12Loydw0rSNeQZMy8Bm3AZaIeZRAgMJK8s0sZEwIraJ8CDc7nNe9nTk1BWjzl1aPErzTjY5yiZ3sskDD97s7rntyDj-OfucxLebSUTa7kK7uMl7u8yVyVKdZtKUGKyUsVWhNgjhOAIng-gs9eBsK_x8q5w5pbczDK0T6cGr3TDaJSVbVGPatZsjkoQgvwdPO13ZrYRSvwRtPJB7WrS31P2RpvrquL8zGfJE4ve-3erbr2X9fSue_4-teAF3ORmK4708g5PVYm1eYkS2KgZwLOdyAKfD4fjzGD_PLyafpnh1lIwG7l-OgTPEnxFYNzM
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEIIXxHUEBhgJniBa4jhx8oDQuEwd2_owbVLfjOMLRKqS0rSa-qf4jZzjJJ3KZW97rV3X9bn4fD43Ql4rq6wTToWFTXjIRcrDnBkQvNKJUljGYo7JySfjbHTOv07SyRb5NeTCYFjloBO9ojaNxjfyPXQpFmDOZOLD7GeIXaPQuzq00OjY4siuLgCyte8PPwN93zB28OXs0yjsuwqEGqyTRYiAh8MlJkqOLfW4EFlaFoXRScRKq6LMaWaNNiDKqWHcKZVGxoCej7nDzrwJrHuD3ISLN0KwJyZi_aaDXjMeF31uTpTkey3cj5jDBoiPAeQD5L5x__k2Af-ybf8O0fzDT-uvv4N75G5vt9L9jtHuky1bPyC3uk6Wq4dkedpMLW0cVVgAAZiSgia1MwD0FCNEFCa9U-x-fKFWoc-fsYZOa3063m9pVVMwQymGitVNW7W4CK0wccXCmKumfWlfXL_EIPoF1cis80fk_FrO_jHZrpvaPiHUiMgVzEVGAaZSHAwVJ3SeuYRbnrqMByQezlnqvtw5dt2YSu92T3LZ0UYCbaSnjYwC8nb9nVlX7OPK2R-RfOuZWKjbf9DMv8te7qWyRW7yQlgNxpBOnYqNBYjIAJhZQH95QHYH4stee7TyktcD8mo9DHKPzhxV22bp5_AswyeFgOx0vLLeCbqWEToFRGxw0cZWN0fq6oevLV6ImGUCfvfdwG-X2_r_UTy9-l-8JLdHZyfH8vhwfPSM3GEoDr565i7ZXsyX9jnYdYvyhRcmSr5dt_T-BrS1XGg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4anUC8IO4EBhgJniBq4jhx8oDQxjZtDKqpYtLeguMLVKqS0rSa-tf4dZyTS6dy2dtea9d1fS4-n88N4LWyyjrplJ_ZSPhCxsJPuUHBK5wspOU8FJSc_GWUHJ2JT-fx-Rb86nNhKKyy14mNojaVpjfyIbkUMzRnEjl0XVjE6f7hh9lPnzpIkae1b6fRssiJXV0gfKvfH-8jrd9wfnjw9eOR33UY8DVaKgufwI_AC00WgtrrCSmTuMgyo6OAF1YFidPcGm1QrGPDhVMqDoxBnR8KR116I1z3BmxLQkUD2N47GJ2O1y885EMTYdZl6gRROqzxtqSMNsR_HAEg4viN27BpGvAvS_fvgM0_vLbNZXh4F-50VizbbdnuHmzZ8j7cbPtarh7AclxNLascU1QOAVmUoV61M4T3jOJFFKXAM-qFfKFWfpNNYw2blno82q3ZpGRolDIKHCurelLTImxCaSwWx9xk2hX6pfULCqlfME2sO38IZ9dy-o9gUFalfQLMyMBl3AVGIcJSAs0WJ3WauEhYEbtEeBD255zrrvg59eCY5o0TPkrzljY50iZvaJMHHrxdf2fWlv64cvYekW89k8p2Nx9U8-95pwVyZbPUpJm0Gk0jHTsVGouAkSNMs4gFUw92euLnnS6p80vO9-DVehi1ALl2VGmrZTNHJAk9MHjwuOWV9U7I0UxAygO5wUUbW90cKSc_mkrjmQx5IvF33_X8drmt_x_F06v_xUu4hZKbfz4enTyD25ykoSmluQODxXxpn6ORtyhedNLE4Nt1C_BvILNiAw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+androgen+receptor+signaling+pathway-related+lncRNAs+in+the+prognosis+and+immune+infiltration+of+breast+cancer&rft.jtitle=Scientific+reports&rft.au=Guo+Huang&rft.au=Hong+Cao&rft.au=Guowen+Liu&rft.au=Juan+Chen&rft.date=2022-11-30&rft.pub=Nature+Portfolio&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft.spage=1&rft.epage=17&rft_id=info:doi/10.1038%2Fs41598-022-25231-0&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_ae98d897ec024c5fa1de8752049e2308
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon